Sysmex Cor (6869)

Currency in JPY
1,850.5
-68.0(-3.54%)
Closed·
6869 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1,846.01,907.0
52 wk Range
1,246.02,015.0
Key Statistics
Bid/Ask
1,849.00 / 1,852.00
Prev. Close
1,918.5
Open
1,897
Day's Range
1,846-1,907
52 wk Range
1,246-2,015
Volume
1.74M
Average Volume (3m)
4.11M
1-Year Change
-7.4519%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
6869 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1,800.0
Downside
-2.73%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Sysmex Cor News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Analyst Ratings

7 Buy
7 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1,800.0
(-2.73% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Goldman Sachs
Buy1,950.00+5.38%1,700.00MaintainAug 10, 2026
JPMorgan
Buy1,600.00-13.54%1,800.00MaintainJun 22, 2026
Nomura/Instinet
Hold1,400.00-24.34%1,600.00MaintainMay 20, 2026
Macquarie
Hold1,450.00-21.64%1,470.00MaintainMay 15, 2026
Morgan Stanley
Hold1,500.00-18.94%2,400.00DowngradeMar 18, 2026

Sysmex Cor Earnings Call Summary for Q2/2026

  • Sysmex missed Q2 2025 forecasts with EPS of 23.2 (vs 24.06 expected) and revenue of ¥126.8B (vs ¥132.89B expected), causing shares to drop 5.65% after hours to ¥1610.
  • The company revised its full-year sales forecast downward to ¥510B and operating income to ¥76B, while improving Q2 operating income ratio to 17.6%.
  • Key challenges include yen depreciation, Chinese market conditions, geopolitical concerns in META region, and US supply chain issues with tariff impacts.
  • Growth opportunities exist in emerging markets like India and Brazil, with planned European market entry for Hinotori medical robot and expansion of hemostasis business in Europe and US.
  • Management expects recovery in Japanese and Chinese markets next year, while focusing on comprehensive laboratory solutions and establishing a training center for Hinotori.
Last Updated: 11/20/2025, 07:56 PM
Read Full Transcript

Earnings

Latest Release
Aug 07, 2026
EPS / Forecast
14.17 / 10.12
Revenue / Forecast
130.67B / 117.36B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 63.79%
Dividend Yield
2.03%
Industry Median 1.66%
Annualized payout
39.00
Paid unevenly
5-Years Growth
+8.45%
Growth Streak

6869 Income Statement

Compare 6869 to Peers and Sector

Metrics to compare
6869
Peers
Sector
Relationship
P/E Ratio
28.3x23.2x−0.4x
PEG Ratio
−1.80−0.660.00
Price/Book
2.3x2.0x2.6x
Price / LTM Sales
2.1x2.1x3.1x
Upside (Analyst Target)
−10.8%16.3%47.9%
Fair Value Upside
Unlock24.3%6.3%Unlock

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers hematology, a major test routinely included in blood tests; Flow Cytometry (FCM) analyzes cell properties by irradiating individual cells with a laser and measuring the intensity of light scattering and fluorescence; urinalysis test checks for the presence of glucose, proteins, and blood in urine; clinical chemistry; hemostasis; immunochemistry; cancer gene testing; and antimicrobial susceptibility testing. The company also provides Caresphere, an ICT solution, which integrates and analyzes real time various data managed through testing instruments and clinical testing information systems, and supports the efficient operation of clinical laboratories; and involved in the medical robotics business. It serves products and services to medical institutions, clinical laboratories, animal hospitals, and research institutes. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

Employees
10861
Market
Japan

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
153.63M25.17%294.74B
Other Institutional Investors
137.75M22.57%264.27B
Public Companies & Retail Investors
318.88M52.25%611.77B
Total
610.26M100.00%1.17T

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Nakatani Foundation6.34%38,692,00074,230,602
Kobe Yamabuki Zaidan, General Foundation5.90%36,000,00069,066,000

People Also Watch

148.53
SPCX
+6.09%
8,290.0
6981
+0.67%
11,295.0
6976
+2.54%
21,580.0
4062
+3.82%
5,472.0
6506
+0.75%

FAQ

What Is the Sysmex Cor (6869) Stock Price Today?

The Sysmex Cor stock price today is 1,850.5 JPY.

What Stock Exchange Does Sysmex Cor Trade On?

Sysmex Cor is listed and trades on the Tokyo Stock Exchange.

What Is the Stock Symbol for Sysmex Cor?

The stock symbol for Sysmex Cor is "6869."

Does Sysmex Cor Pay Dividends? What’s The Current Dividend Yield?

The Sysmex Cor dividend yield is 2.03%.

What Is the Sysmex Cor Market Cap?

As of today, Sysmex Cor market cap is 1.12T JPY.

What Is Sysmex Cor's Earnings Per Share (TTM)?

The Sysmex Cor EPS (TTM) is 63.8.

When Is the Next Sysmex Cor Earnings Date?

Sysmex Cor will release its next earnings report on Nov 11, 2026.

From a Technical Analysis Perspective, Is 6869 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Sysmex Cor Stock Split?

Sysmex Cor has split 4 times.

How Many Employees Does Sysmex Cor Have?

Sysmex Cor has 10861 employees.

What is the current trading status of Sysmex Cor (6869)?

As of Aug 17, 2026, Sysmex Cor (6869) is trading at a price of 1,850.5 JPY, with a previous close of 1,918.5 JPY. The stock has fluctuated within a day range of 1,846.0 JPY to 1,907.0 JPY, while its 52-week range spans from 1,246.0 JPY to 2,015.0 JPY.

What Is Sysmex Cor (6869) Price Target According to Analysts?

The average 12-month price target for Sysmex Cor is 1,800.0 JPY, with a high estimate of 3300 JPY and a low estimate of 1380 JPY. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an -2.73% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.